WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 562990
CAS#: 1032822-42-6
Description: PTIQ is a neuroprotective compound. It inhibits tetrahydro-L-biopterin-induced cytotoxicity and increases in matrix metalloproteinase-3 (MMP-3) levels in CATH.a cells (IC50s = 1.8 and 0.06 µM, respectively). PTIQ inhibits LPS-induced production of MMP-3, TNF-α, and COX-2 in BV-2 microglia (IC50s = 2.4, 6.5, and 9.3 µM, respectively). In vivo, PTIQ (3 and 30 mg/kg) increases survival of striatal nigral dopaminergic neurons, reduces microglial activation, and alleviates motor deficits in a mouse model of MPTP-induced Parkinson’s disease.
MedKoo Cat#: 562990
Name: PTIQ
CAS#: 1032822-42-6
Chemical Formula: C13H17NO3
Exact Mass: 235.1208
Molecular Weight: 235.28
Elemental Analysis: C, 66.36; H, 7.28; N, 5.95; O, 20.40
Synonym: PTIQ;
IUPAC/Chemical Name: 1-(3,4-Dihydro-7-hydroxy-6-methoxy-2(1H)-isoquinolinyl)-1-propanone
InChi Key: BEDYMEDICHGLSE-UHFFFAOYSA-N
InChi Code: InChI=1S/C13H17NO3/c1-3-13(16)14-5-4-9-7-12(17-2)11(15)6-10(9)8-14/h6-7,15H,3-5,8H2,1-2H3
SMILES Code: CCC(N1CC2=C(C=C(OC)C(O)=C2)CC1)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 235.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Mautone JA, Marcelle E, Tresco KE, Power TJ. Assessing the Quality of Parent-Teacher Relationships for Students with ADHD. Psychol Sch. 2015 Feb;52(2):196-207. PubMed PMID: 25663718; PubMed Central PMCID: PMC4316369.
2: Kitanaka J, Kitanaka N, Hall FS, Uhl GR, Asano H, Chatani R, Hayata S, Yokoyama H, Tanaka KI, Nishiyama N, Takemura M. Pretreatment with nomifensine or nomifensine analogue 4-phenyl-1,2,3,4-tetrahydroisoquinoline augments methamphetamine-induced stereotypical behavior in mice. Brain Res. 2012 Feb 23;1439:15-26. doi: 10.1016/j.brainres.2011.12.043. Epub 2011 Dec 31. PubMed PMID: 22265332; PubMed Central PMCID: PMC4093904.
3: Son HJ, Lee JA, Shin N, Choi JH, Seo JW, Chi DY, Lee CS, Kim EM, Choe H, Hwang O. A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP. Br J Pharmacol. 2012 Apr;165(7):2213-27. doi: 10.1111/j.1476-5381.2011.01692.x. PubMed PMID: 21951056; PubMed Central PMCID: PMC3413858.
4: Tateyama M, Nagao T, Ohta S, Hirobe M, Ono H. 4-Phenyltetrahydroisoquinoline, but not nomifensine or cocaine, inhibits methamphetamine-induced dopamine release. Eur J Pharmacol. 1993 Aug 10;240(1):51-6. PubMed PMID: 8405121.
5: Tateyama M, Ohta S, Nagao T, Hirobe M, Ono H. Inhibitory effect of 4-phenyltetrahydroisoquinoline on locomotion and dopamine release induced by micro-injection of methamphetamine into the nucleus accumbens of the rat. Neuropharmacology. 1993 Aug;32(8):761-6. PubMed PMID: 8413840.
6: Tateyama M, Ohta S, Nagao T, Hirobe M, Ono H. Effect of 4-phenyl-1,2,3,4-tetrahydroisoquinoline on ambulation induced by injection of methamphetamine into the nucleus accumbens in rats. Neuropharmacology. 1993 Mar;32(3):243-8. PubMed PMID: 8474620.
7: Siu PM, Vick JA. Studies on the mechanism of action of 1-(2-methyl-3-hydroxy-5-hydroxy-methyl-4-pyridyl)-6,7-dihydroxy-1,2,3, 4- tetrahydroisoquinoline (PTIQ) on blood pressure in the anesthetized dog. Res Commun Chem Pathol Pharmacol. 1989 Jun;64(3):421-33. PubMed PMID: 2781139.
8: Siu PM, Vick JA. Evidence for a central muscarinic action by 1-(2-methyl-3-hydroxy-5-hydroxymethyl-4-pyridyl)-6,7-dihydroxy-1,2, 3,4-tetrahydroisoquinoline in regulating blood pressure in the anesthetized dog. Arch Int Pharmacodyn Ther. 1987 Jan;285(1):43-9. PubMed PMID: 3579425.
9: Siu PM, Vick JA. Effect of a specific tetrahydroisoquinoline on the blood pressure in animals. Res Commun Chem Pathol Pharmacol. 1985 May;48(2):203-8. PubMed PMID: 4023409.
